

Lebenslauf

Name: Nicolaus Martin Kröger

Geburtsort: Freiburg im Breisgau

Titel: Prof. Dr. med.

Studium:

1982 – 1988: Humanmedizin: Turin, Marburg (Humanbiologie),
Hamburg

1988: MD Anderson Hospital Houston, Texas

1989: Verleihung des Doktorgrades

1988 – 1992: internistische Weiterbildung, Israelitisches Krankenhaus
Hamburg

1992 – 1996: hämato-onkologische Weiterbildung, Universitätsklinikum
Hamburg-Eppendorf

1995: Facharzt für Innere Medizin

1995: ESMO Examen

1997: Facharzt für Hämatologie und Internistische Onkologie

1997: Anerkennung des Schwerpunktes Internistische Onkologie
und Hämatologie

2000: Habilitation: Verleihung der Venia legendi

2006: Ernennung zum Professor

seit 2011: Klinikdirektor der Interdisziplinären Klinik und Poliklinik für
Stammzelltransplantation

Auszeichnungen

2005:	Werner-Otto-Preis für Medizinische Forschung
2010:	Preis der Hamburger Krebsgesellschaft
2015:	van-Bekkum-Award der European Group for Blood and Marrow Transplantation (EBMT)
1999:	Scientific Secretary des 25th Annual EBMT Kongresses (Hamburg)
2006 – 2011:	Chairman MDS Subcommittee der Chronic Malignancy Working Party (CMWP)
2012 -	Chairman der Chronic Malignancy Working Party (EBMT)
2014 -	Chairman Scientific Council der EBMT
2014 -	Sprecher der Deutschen Arbeitsgemeinschaft für Blut- und Knochenmarktransplantation e. V.
2014 -	Scientific Council of European School of Hematology (ESH)
2015 -	Editorial Board of EHA
2015/2016:	Editorial Board of Blood, Haematologica, and Bone Marrow Transplantation

Table of contents

A	Original publications (first or senior author).....	3
	2015.....	3
	2014.....	4
	2013.....	5
	2012.....	6
	2011.....	7
	2010.....	8
	2009.....	9
	2008.....	10
	2007.....	10
	2006.....	11
	2005.....	12
	2004.....	12
	2003.....	13
	2002.....	13
	2001.....	14
	2000.....	14
	1999.....	15
	1998.....	15
	1996 und älter	15
B	Coauthor in original publications	17
	2015.....	17
	2014.....	19
	2013.....	21
	2012.....	23
	2011.....	24
	2010.....	25
	2009.....	27
	2008.....	28
	2007.....	29
	2006.....	29
	2005.....	30
	2004.....	30
		1

2003.....	31
2002.....	32
2001.....	32
2000.....	33
1999.....	33
1998.....	34
1997.....	34
1996 und älter	35

2015

1. **Kröger N, Bornhäuser M, Stelljes M, Pichlmeier U, Trensche R, Schmid C, Arnold R, Martin H, Heinzelmann M, Wolschke C, Meyer RG, Bethge W, Kobbe G, Ayuk F, Gökbuget N, Hölzer D, Zander A, Beelen D.** Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide, and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). *Bone Marrow Transplant.* 2015 Sep 14 [Epub ahead of print]
2. **Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, Duarte R, Peters C, Garderet L, Schönland S, Gratwohl A, Niederwieser D, de Witte T, Kröger N.** Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. *Bone Marrow Transplant.* 2015 Sep 14 [Epub ahead of print]
3. **Kröger N, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, BArbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cerventes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G.** Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. *Leukemia.* 2015 Aug 21 [Epub ahead of print]
4. **Kröger N.** Current challenges in stem cell transplantation in myelofibrosis. *Curr Hematol Malig Rep.* 2015 Aug 19 [Epub ahead of print]
5. **Auner HW, Garderet L, Kröger N.** Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. *Br J Haematol.* 2015 Jul 27 [Epub ahead of print]
6. **Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, Bornhäuser M, Cornelissen J, Volin L, Mufti G, Chalandon Y, Ganser A, Bruno B, Niederwieser D, Kobbe G, Schwerdtfeger R, de Witte T, Robin M, Kröger N.** Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Br J Haematol.* 2015 Jul 26 [Epub ahead of print]
7. **Ayuk F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.** Prognostic factors for survival of patients with newly diagnosed chronic GvHD according to NIH criteria. *Ann Hematol.* 2015;94(10):1727-32.
8. **Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuk F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübiger T, Wolschke C, Bacher U, Kröger N.** Atovaquone for prophylaxis of toxoplasmosis after allogeneic haematopoietic stem cell transplantation. *Acta Haematol.* 2015;134(3):146-54.
9. **Kröger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, Vannucchi A, Cazzola M, Morra E, Zabelina T, Maffioli M, Pereira A, Beelen D, Deeg HJ, Passamonti F.** Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. *Blood.* 2015; 125(21):3347-50.
10. **Trivai I, Stübiger T, Niebuhr B, Hussein K, Tsiftoglou A, Fehse B, Stocking C, Kröger N.** CD133 marks a stem cell population that drives human Primary Myelofibrosis. *Haematologica.* 2015;100(6):768-79.
11. **Derlin T, Clauditz TS, Kröger N.** 18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis. *Clin Nucl Med.* 2015 Jun;40(6):521-2.
12. **Derlin T, Büsche G, Kröger N.** Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation. *Nucl Med Rev Cent East Eur.* 2015;18(1):35-6
13. **Derlin T, Alchalby H, Bannas P, Veldhoen S, Apostolova I, Trivai I, Bengel FM, Kröger N.** Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study. *Eur J Nucl Med Mol Imaging.* 2015 Apr;42(5):696-705. doi: 10.1007/s00259-014-2983-4.

14. **Koenecke C, Göhring G, de Wreede LC, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N;** MDS subcommittee of the Chronic Malignancies Working Party of the EBMT. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. *Haematologica*. 2015 Mar;100(3):400-8. doi: 10.3324/haematol.2014.116715.
15. **Robin M, Ruggeri A, Labopin M, Niederwieser D, Tabrizi R, Sanz G, Bourhis JH, van Biezen A, Koenecke C, Blaise D, Tischer J, Craddock C, Maillard N, Mohty M, Russel N, Schetelig J, Finke J, Gluckman E, de Witte TM, Rocha V, Kroger N.** Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. *Biol Blood Marrow Transplant*. 2015 Mar;21(3):489-95. doi: 10.1016/j.bbmt.2014.11.675.
16. **Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ, Moreau P, Attal M, Marit G, Russell N, Brune M, Cook G, Sonneveld P, Schönland S, Garderet L, Kröger N.** Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. *Bone Marrow Transplant*. 2015 Feb;50(2):209-15. doi: 10.1038/bmt.2014.255.

2014

17. **de Witte TM, Bowen D, Robin M, Malcovati L, Mufti G, Niederwieser D, Yakoubagha I, Kröger N;** Myelodysplastic Syndrome Stem Cell Transplant Guidelines Preparation Group from the Chronic Malignancies Working Party, European Group for Blood and Marrow Transplantation and European LeukemiaNet. Should patients with high-risk or transformed myelodysplastic syndrome proceed directly to allogeneic transplant without prior cytoreduction by remission-induction chemotherapy or hypomethylating agent therapy? *Clin Lymphoma Myeloma Leuk*. 2014 Sep;14 Suppl:S42-5. doi: 10.1016/j.clml.2014.06.015.
18. **Alchalby H, Kröger N.** Allogeneic stem cell transplant vs. Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera. *Clin Lymphoma Myeloma Leuk*. 2014 Sep;14 Suppl:S36-41. doi: 10.1016/j.clml.2014.06.012.
19. **Hussein AA, Halkes CM, Socié G, Tichelli A, von dem Borne PA, Schaap MN, Foa R, Ganser A, Dufour C, Bacigalupo A, Locasciulli A, Aljurf M, Peters C, Robin M, van Biezen AA, Volin L, De Witte T, Marsh J, Passweg JR, Kröger N;** Severe Aplastic Anemia and Chronic Malignancies Working Parties of the European Group for Blood and Marrow Transplantation. Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2014 Sep;20(9):1448-50. doi: 10.1016/j.bbmt.2014.05.028. Epub 2014 Jun 6.
20. **Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuk F, Kröger N.** JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. *Leukemia*. 2014 Aug;28(8):1736-8. doi: 10.1038/leu.2014.86. Epub 2014 Feb 26. No abstract available.
21. **Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuk F, von Hünenbein N, Kvasnicka HM, Thiele J, Kreipe HH, Büsche G.** Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. *Biol Blood Marrow Transplant*. 2014 Jun;20(6):812-5. doi: 10.1016/j.bbmt.2014.02.019. Epub 2014 Mar 1.
22. **Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.** Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2014 May;99(5):916-21. doi: 10.3324/haematol.2013.094284. Epub 2014 Jan 3.

23. **Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander AR, Kröger N.** Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation. *Ann Hematol.* 2014 May;93(5):855-61. doi: 10.1007/s00277-013-1957-0. Epub 2013 Nov 19.
24. **Atanackovic D, Luetkens T, Kröger N.** Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. *Leukemia.* 2014 May;28(5):993-1000. doi: 10.1038/leu.2013.310. Epub 2013 Oct 23. Review.
25. **Stübig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder TM, Fehse B, Kröger N.** 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. *Mediators Inflamm.* 2014;2014:418292. doi: 10.1155/2014/418292. Epub 2014 Mar 13.
26. **Langebrake C, Rohde H, Lellek H, Wolschke C, Kröger N.** Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice. *Clin Transplant.* 2014 Mar;28(3):286-91. doi: 10.1111/ctr.12310. Epub 2014 Jan 30.
27. **Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuk F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N.** Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. *Eur J Haematol.* 2014 Mar;92(3):189-94. doi: 10.1111/ejh.12223. Epub 2013 Nov 21.
28. **Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuk F, Reckhaus ML, Blaise D, Kröger N.** CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies. *Biol Blood Marrow Transplant.* 2014 Mar;20(3):382-6. doi: 10.1016/j.bbmt.2013.11.034. Epub 2013 Dec 7.
29. **Kröger N, Stübig T, Atanackovic D.** Immune-modulating drugs and hypomethylating agents to prevent or treat relapse after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant.* 2014 Feb;20(2):168-72. doi: 10.1016/j.bbmt.2013.09.009. Epub 2013 Sep 22. Review.
30. **Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn JY, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N;** Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2014 Feb;20(2):279-81. doi: 10.1016/j.bbmt.2013.10.027. Epub 2013 Nov 4.
31. **Wolschke C, Zabelina T, Ayuk F, Alchalby H, Berger J, Klyuchnikov E, Pein UM, Schumacher S, Amsfeld G, Adjallé R, Wortmann F, Lellek H, Randenborgh A, Zander A, Kröger N.** Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation. *Bone Marrow Transplant.* 2014 Jan;49(1):126-30. doi: 10.1038/bmt.2013.143. Epub 2013 Sep 16.

2013

32. **Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L, Robin M, van Gelder M, Finke J, Bornhäuser M, Kobbe G, Germing U, de Witte T, Kröger N.** Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data. *PLoS One.* 2013 Oct 7;8(10):e74368. doi: 10.1371/journal.pone.0074368.
33. **Kröger N.** From nuclear to a global family: more donors for MDS. *Blood.* 2013 Sep 12;122(11):1848-50. doi: 10.1182/blood-2013-07-515494. No abstract available.

34. **Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N, Volin L, Janssen J, Nguyen Quoc S, Michallet M, Schoemans H, El Cheikh J, Petersen E, Guilhot F, Schönland S, Ahlberg L, Morris C, Garderet L, de Witte T, Kröger N;** Plasma Cell Dyscrasia Sub-committee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant.* 2013 Nov;48(11):1395-400. doi: 10.1038/bmt.2013.73. Epub 2013 May 27.
35. **Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Schönland S, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N;** EBMT Chronic Malignancies Working Party Plasma Cell Disorders Subcommittee. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. *Blood.* 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.
36. **Ayuk F, Zabelina T, Wortmann F, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N.** Donor choice according to age for allo-SCT for AML in complete remission. *Bone Marrow Transplant.* 2013 Aug;48(8):1028-32. doi: 10.1038/bmt.2013.14. Epub 2013 Feb 18.
37. **Oyekunle A, Zander AR, Binder M, Ayuk F, Zabelina T, Christopeit M, Stübiger T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N.** Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. *Ann Hematol.* 2013 Apr;92(4):487-96. doi: 10.1007/s00277-012-1650-8. Epub 2012 Dec 19.
38. **van Gelder M, de Wreede LC, Schetelig J, van Biezen A, Volin L, Maertens J, Robin M, Petersen E, de Witte T, Kröger N;** EBMT Chronic Malignancies Working Party. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. *Leukemia.* 2013 Apr;27(4):879-88. doi: 10.1038/leu.2012.297. Epub 2012 Oct 16.
39. **Wolschke C, Stübiger T, Hegenbart U, Schönland S, Heinzlmann M, Hildebrandt Y, Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N.** Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. *Exp Hematol.* 2013 Feb;41(2):134-142.e3. doi: 10.1016/j.exphem.2012.10.004. Epub 2012 Oct 17.
40. **Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzlmann M, Zeschke S, Bacher U, Stübiger T, Fehse B, Zander AR.** Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. *Biol Blood Marrow Transplant.* 2013 Mar;19(3):398-404. doi: 10.1016/j.bbmt.2012.10.008. Epub 2012 Oct 16.
41. **Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger KH, Burchert A, Stübiger T, Wolschke C, Ayuk F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander AR.** Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. *Bone Marrow Transplant.* 2013 Mar;48(3):403-7. doi: 10.1038/bmt.2012.142. Epub 2012 Aug 6.
42. **Kröger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A, Milpied N, Volin L, Mohty M, Leblond V, Blaise D, Finke J, Schaap N, Robin M, de Witte T;** MDS subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. *Leukemia.* 2013 Mar;27(3):604-9. doi: 10.1038/leu.2012.210. Epub 2012 Jul 23.

2012

43. **Kröger N, Mohty M, Nagler A, Yi Q.** Immunotherapy for multiple myeloma. *Clin Dev Immunol.* 2012;2012:797165. doi: 10.1155/2012/797165. Epub 2012 Dec 30. No abstract available.

44. **Klyuchnikov E, Holler E, Bornhäuser M, Kobbe G, Nagler A, Shimoni A, Könecke C, Wolschke C, Bacher U, Zander AR, Kröger N.** Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. *Br J Haematol.* 2012 Oct;159(2):172-81. doi: 10.1111/bjh.12013. Epub 2012 Aug 22.
45. **Heidenreich S, Zu Eulenburg C, Hildebrandt Y, Stübiger T, Sierich H, Badbaran A, Eiermann TH, Binder TM, Kröger N.** Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma. *Clin Dev Immunol.* 2012;2012:652130. doi: 10.1155/2012/652130. Epub 2012 Jul 10.
46. **Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N.** Role of interleukin 16 in multiple myeloma. *J Natl Cancer Inst.* 2012 Jul 3;104(13):1005-20. doi: 10.1093/jnci/djs257. Epub 2012 Jun 28.
47. **Kröger N.** Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. *Blood.* 2012 Jun 14;119(24):5632-9. doi: 10.1182/blood-2011-12-380162. Epub 2012 Apr 13. Review.
48. **Kröger N, Kvasnicka M, Thiele J.** Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. *Fibrogenesis Tissue Repair.* 2012 Jun 6;5 Suppl 1:S25. [Epub ahead of print]
49. **Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka HM, Büsche G, Ayuk F, Bacher U, Zander AR, Kröger N.** Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. *Br J Haematol.* 2012 Apr;157(1):75-85. doi: 10.1111/j.1365-2141.2011.09009.x. Epub 2012 Jan 27.
50. **Derlin T, Weber C, Habermann CR, Herrmann J, Wisotzki C, Ayuk F, Wolschke C, Klutmann S, Kröger N.** 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. *Eur J Nucl Med Mol Imaging.* 2012 Mar;39(3):493-500. doi: 10.1007/s00259-011-1993-8. Epub 2011 Nov 24.
51. **Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübiger T, Ayuk FA, Zander AR, Kröger N.** Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT. *Bone Marrow Transplant.* 2012 Jan;47(1):143-5. doi: 10.1038/bmt.2011.17. Epub 2011 Feb 28.

2011

52. **Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Kröger N.** Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. *Am J Hematol.* 2011 Nov;86(11):918-22. doi: 10.1002/ajh.22141. Epub 2011 Sep 2.
53. **Bacher U, Ocheni S, Schafhausen P, Oyekunle A, Dierlamm J, Zander AR, Bokemeyer C, Haferlach T, Kröger N.** Unusual course of myelodysplastic syndrome with presumed familial origin. *Acta Haematol.* 2011;126(4):234-7. Epub 2011 Sep 22.
54. **Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübiger T, Hilde-Brandt Y, Atanackovic D, Alchalby H, Ayuk F, Zander AR, Bacher U, Eiermann T.** Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. *Leukemia.* 2011 Oct;25(10):1657-61. doi: 10.1038/leu.2011.138. Epub 2011 Jun 7.
55. **Atanackovic D, Panse J, Hildebrandt Y, Jadcak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander AR, Marx AH, Bokemeyer C, Kröger N.** Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. *Haematologica.* 2011 Oct;96(10):1512-20. Epub 2011 May 23.
56. **Bacher U, Haferlach T, Schnittger S, Kreipe H, Kröger N.** Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. *Br J Haematol.* 2011 Apr;153(2):149-67. Epub 2011 Mar 9.
57. **Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübiger T, Bacher U, Amtsfeld G, Merle E, Reckhaus ML, Fehse B, Wolschke C, Adjallé R, Ayuk F, Zander A, Kröger N.** Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2011 Mar;17(3):374-83. Epub 2010 Jul 15.

58. **Kröger N.** Approaches to relapse after allogeneic stem cell transplantation. *Curr Opin Oncol.* 2011 Mar;23(2):203-8. Review.
59. **Bacher U, Haferlach T, Fehse B, Schnittger S, Kröger N.** Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia. *ScientificWorldJournal.* 2011 Feb 3;11:310-9. Review.
60. **Kröger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T; MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT).** Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. *Haematologica.* 2011 Feb;96(2):291-7. Epub 2010 Oct 22.
61. **Kröger N, Miyamura K, Bishop MR.** Minimal residual disease following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2011 Jan;17(1 Suppl):S94-100. Review

2010

62. **Kröger N.** Approaches to relapse after allogeneic stem cell transplantation. *Curr Opin Oncol.* 2010 Dec 13.
63. **Kröger N.** Unrelated stem cell transplantation for patients with multiple myeloma. *Curr Opin Hematol.* 2010 Nov;17(6):538-43.
64. **Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Thiede C, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander AR, Kröger N.** Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. *Blood.* 2010 Nov 4;116(18):3572-81.
65. **Kröger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, De Witte T.** Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. *Haematologica.* 2010 Oct 22.
66. **Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS.** NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. *Biol Blood Marrow Transplant.* 2010 Oct;16(10):1325-46.
67. **Kröger N, Bacher U, Bader P, Böttcher S, Borowitz MJ, Dreger P, Khouri I, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS.** NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. *Biol Blood Marrow Transplant.* 2010 Sep;16(9):1187-211. Erratum in: *Biol Blood Marrow Transplant.* 2010 Dec;16(12):1752. Macapintac, Homer [corrected to Macapinlac, Homer A].
68. **Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR, Kröger N.** Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. *Bone Marrow Transplant.* 2010 Sep;45(9):1404-7. Epub 2010 Jan 11.
69. **Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübiger T, Bacher U, Amtsfeld G, Merle E, Reckhaus ML, Fehse B, Wolschke C, Adjallé R, Ayuk F, Zander A, Kröger N.** Purification of CD4(+) T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant.* 2010 Jul 14.
70. **Kröger N, Einsele H, Derigs G, Wandt H, Krüll A, Zander A.** Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. *Biol Blood Marrow Transplant.* 2010 Jun;16(6):861-4. Epub 2010 Feb 6.
71. **Atanackovic D, Hildebrandt Y, Jadcak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C, Kröger N.** Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. *Haematologica.* 2010 May;95(5):785-93. Epub 2009 Dec 16.

72. **Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornhäuser M, Thiede C, Baurmann H, Bethge W, Hildebrandt Y, Bacher U, Fehse B, Zander AR, Kröger N.** Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis. *Blood*. 2010 May 20.
73. **Kröger N, Asenova S, Gerritzen A, Bacher U, Zander A.** Questionable role of free light chain assay ratio to determine stringent complete remission in multiple myeloma patients. *Blood*. 2010 Apr 22;115(16):3413-4; author reply 3414-5.
74. **Alchalby H, Kröger N.** Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis. *Curr Hematol Malig Rep*. 2010 Apr;5(2):53-61. Review.
75. **Lioznov M, El-Cheikh J Jr, Hoffmann F, Hildebrandt Y, Ayuk F, Wolschke C, Atanackovic D, Schilling G, Badbaran A, Bacher U, Fehse B, Zander AR, Blaise D, Mohty M, Kröger N.** Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. *Bone Marrow Transplant*. 2010 Feb;45(2):349-53. Epub 2009 Jul. 6.
76. **Cavattoni I, Zabelina T, Ayuk F, Wolschke C, Bacher U, Zander A, Kröger N.** Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation. *Leuk Lymphoma*. 2010 Jan;51(1):146-8.
77. **Kröger N, Shimoni A, Schilling G, Schwerdtfeger R, Bornhäuser M, Nagler A, Zander AR, Heinzelmann M, Brand R, Gahrton G, Morris C, Niederwieser D, de Witte T.** Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. *Br J Haematol*. 2010 Jan;148(2):323-31.
78. **Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR, Kröger N.** Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. *Bone Marrow Transplant*. 2010 Jan 11.

2009

79. **Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM.** Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood*. 2009 Dec 17;114(26):5264-70.
80. **Kröger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrandt Y, Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A.** Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. *Exp Hematol*. 2009 Jul;37(7):791-8.
81. **Ayuk F, Maywald N, Hannemann S, Larsen U, Zander A, Kröger N.** Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. *Anticancer Res*. 2009 Apr;29(4):1355-60.
82. **Klyuchnikov E, Kröger N.** Sensitising leukemic cells by targeting microenvironment. *Leuk Lymphoma*. 2009 Mar;50(3):319-20.
83. **Kröger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G, Lellek H, Schrum J, Erttmann R, Eiermann T, Zander A.** HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. *Biol Blood Marrow Transplant*. 2009 Apr;15(4):454-62.
84. **Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, Devergie A, Ruutu T, Cornish J, Ljungman P, Gratwohl A, Cordonnier C, Beelen D, Deconinck E, Symeonidis A, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT).** Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. *Haematologica*. 2009 Apr;94(4):542-9

85. **Ocheni S, Zabelina T, Bacher U, Ayuk F, Zander A, Kröger N.** Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors. *Leuk Lymphoma*. 2009 Apr;50(4):612-8.
86. **Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A.** JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. *Blood*. 2009 Feb 19;113(8):1866-8.
87. **Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander AR, Bokemeyer C, Kröger N.** Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. *Clin Cancer Res*. 2009 Feb 15;15(4):1343-52.
88. **Ayuk F, Zander A, Kröger N.** Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma. *Ann Hematol*. 2009 May;88(5):401-4. Review.
89. **Bacher U, Badbaran A, Fehse B, Zabelina T, Zander AR, Kröger N.** Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation. *Exp Hematol*. 2009 Jan;37(1):135-42.

2008

90. **Ayuk F, Perez-Simon JA, Shimon A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer HG, Alegre A, Lahuerta JJ, Atanackovic D, Wolschke C, Nagler A, Zander AR, San Miguel JF, Kröger N.** Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. *Haematologica*. 2008 Sep;93(9):1343-50.
91. **Bacher U, Zander AR, Haferlach T, Schnittger S, Fehse B, Kröger N.** Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. *Bone Marrow Transplant*. 2008 Aug;42(3):145-57. Review.
92. **Ayuk FA, Atassi N, Schuch G, Mina S, Fang L, Bokemeyer C, Fehse B, Zander AR, Kröger N.** Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia. *Leuk Res*. 2008 Aug;32(8):1200-6.
93. **Schilling G, Hansen T, Shimon A, Zabelina T, Pérez-Simón JA, Gutierrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Nagler A, Kröger N.** Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. *Leukemia*. 2008 Jun;22(6):1250-5. Erratum in: *Leukemia*. 2008 Oct;22(10):1974. Simon-Perez, J-A [corrected to Pérez-Simón, J-A]; Miguel, JS [corrected to San Miguel, J].
94. **Lioznov M, Badbaran A, Fehse B, Bacher U, Zander AR, Kröger NM.** Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques. *Bone Marrow Transplant*. 2008 May;41(10):913-6.
95. **Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander AR, Fehse B, Bokemeyer C, Kröger N.** CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. *Haematologica*. 2008 Mar;93(3):423-30.
96. **Kröger N, Mesa RA.** Choosing between stem cell therapy and drugs in myelofibrosis. *Leukemia*. 2008 Mar;22(3):474-86. Review.
97. **Kröger N.** Epigenetic Modulation and Other Options to Improve Outcome of Stem Cell Transplantation in MDS. *Hematology Am Soc Hematol Educ Program*. 2008;2008:60-7.

2007

98. **Goekkurt E, Stoecklacher J, Stueber C, Wolschke C, Eiermann T, Iacobelli S, Zander AR, Ehninger G, Kröger N.** Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. *Anticancer Res*. 2007 Nov-Dec;27(6C):4377-80.

99. **Kröger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhäuser M, Bethge W, Schubert J, de Witte T, Kvasnicka HM; MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.** Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. *Exp Hematol.* 2007 Nov;35(11):1719-22.
100. **de Witte T, Suciu S, Brand R, Muus P, Kröger N.** Autologous stem cell transplantation in myelodysplastic syndromes. *Semin Hematol.* 2007 Oct;44(4):274-7. Review.
101. **Kröger N.** Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. *Leukemia.* 2007 Sep;21(9):1851-8. Review.
102. **Thiele J, Varus E, Siebolts U, Kvasnicka HM, Wickenhauser C, Metz KA, Beelen DW, Ditschkowski M, Zander A, Kröger N.** Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation. *Histol Histopathol.* 2007 Apr;22(4):365-72.
103. **Atanackovic D, Arfsten J, Cao Y, Gnjjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, Ritter G, Eiermann T, Hossfeld DK, Zander AR, Jungbluth AA, Old LJ, Bokemeyer C, Kröger N.** Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. *Blood.* 2007 Feb 1;109(3):1103-12.
104. **Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M, Reiter A, Zabelina T, Zander AR, Fehse B.** Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. *Blood.* 2007 Feb 1;109(3):1316-21.
105. **Mösbauer U, Ayuk F, Schieder H, Lioznov M, Zander AR, Kröger N.** Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation. *Haematologica.* 2007 Feb;92(2):275-6.

2006

106. **Oyekunle A, Koehl U, Schieder H, Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kröger N.** CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. *Cytotherapy.* 2006;8(4):375-80.
107. **Kröger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A.** Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. *Exp Hematol.* 2006 Jun;34(6):770-5.
108. **Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, Ayuk F, Zander A, Fehse B.** Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly-sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma. *Exp Hematol.* 2006 May;34(5):688-94.
109. **Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuk F, Dahlke J, Eiermann T, Zander A.** Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. *Transplantation.* 2006 Oct 27;82(8):1024-30.
110. **Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T; Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).** Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. *Bone Marrow Transplant.* 2006 Jan;37(2):183-9.
111. **Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A.** Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). *Bone Marrow Transplant.* 2006 Feb;37(4):339-44.

112. **Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hanel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U.** Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. *J Clin Oncol.* 2006 Aug 20;24(24):3919-26.
113. **Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T.** Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. *Clin Cancer Res.* 2006 Jan 1;12(1):159-68.

2005

114. **Ayuk FA, Fang L, Fehse B, Zander AR, Kröger N.** Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells. *Exp Hematol.* 2005 Dec;33(12):1531-6.
115. **Kröger N.** Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma. *Leuk Lymphoma.* 2005 Jun;46(6):813-21.
116. **Thiele J, Kvasnicka HM, Dietrich H, Stein G, Hann M, Kaminski A, Rathjen N, Metz KA, Beelen DW, Ditschkowski M, Zander A, Kröger N.** Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. *Histol Histopathol.* 2005 Jul;20(3):879-89.
117. **Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI;** Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. *Br J Haematol.* 2005 Jun;129(5):631-43.
118. **Kröger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N, Fehse N, Waschke O, Fehse B, Kvasnicka HM, Thiele J, and Zander A:** Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. *British Journal of Haematology* 2005; 128: 609-697
119. **Fang L, Fehse B, Engel M, Zander A, Kröger N.** Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. *Transplantation.* 2005 Feb 15;79(3):369-71
120. **Kröger N, Brand R, van Biezen A, Bron D, Blaise D, Hellstrom-Lindberg E, Gahrton G, Powles R, Littlewood T, Chapuis B, Zander A, Koza V, Niederwieser D, de Witte T;** Myelodysplastic Syndromes Subcommittee of the Chronic Leukaemia Working Party, European Blood and Marrow Transplantation Group. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes. *Bone Marrow Transplant.* 2005 Jan;35(1):37-43.

2004

121. **Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer HG, Zabelina T, Zander AR, Kröger N.** Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. *Leukemia.* 2004 Mar;18(3):659-62.
122. **Kröger N, Shimoni A, Zagrivnaja M, Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander AR.** Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. *Blood.* 2004 Nov 15;104(10):3361-3.
123. **Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR.** Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. *Biol Blood Marrow Transplant.* 2004 Oct;10(10):698-708.

124. **Kröger N.** Allogeneic stem cell transplantation following dose-reduced conditioning in patients with hematologic systemic diseases or solid tumors. *Ther Umsch.* 2004 Jun;61(6):385-8.
125. **Kröger N, Sonnenberg S, Cortes-Dericks L, Freiburger P, Mollnau H, Zander AR.** Kinetic of G-CSF and CD34⁺ cell mobilization after once or twice daily stimulation with recombinant human granulocyte stimulating factor (lenograstim) in healthy volunteers. An intraindividual cross-over study. *Transfusion.* 2004 Jan;44(1):104-10.
126. **Kröger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A, Perez-Simon JA, San Miguel JF, Kiehl M, Fauser A, Schwerdtfeger R, Wandt H, Sayer HG, Myint H, Klingemann H, Zabelina T, Dierlamm J, Hinke A, Zander AR.** Deletion of chromosome 13q14 detected by fluorescence in situ hybridization as prognostic factor following allogeneic dose-reduced stem cell transplantation in patients with multiple myeloma. *Blood.* 2004 Jun 1; 103(11): 4056-61

2003

127. **Kröger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, and Rosti G, on behalf of the Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation, the German Adjuvant Breast Cancer Study Group and the University of California, San Francisco.** Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. *Bone Marrow Transplant.* 2003 Dec;32(12):1153-7.
128. **Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuk F, Krull A, Zander A.** Myeloablative intensified conditioning regimen with in vivo T cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-Group Multiple Myeloma (DSMM). *Bone Marrow Transplant* 2003; 31(11): 973-979
129. **Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schafer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group.** Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. *Ann Hematol.* 2003 Jun;82(6):336-42.
130. **Kröger N, Zander AR, Martinelli G, Ferrante P, Moraleta JM, Da Prada GA, Demirer T, Socie G, Rosti G; European Group for Blood and Marrow Transplantation.** Low incidence of secondary myelodysplasia and acute myeloid leukaemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: A study of the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation (EBMT). *Annals of Oncology* 2003; 14 (4): 554-558

2002

131. **Kröger N, Zabelina T, Renges H, Krüger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuk F, Erttmann R, Kabisch H, Zander AR:** Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin. *Annals of Hematology* 2002; 81: 627-631
132. **Kröger N, Zabelina T, Guardiola P, Runde V, Sierra J, van Biezen A, Niederwieser D, Zander AR, de Witte T.** Allogeneic Stem Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. A Report on Behalf of the Chronic Leukemia Working Party of The European Group for Blood and Marrow Transplantation (EBMT). *British Journal of Haematology* 2002; 118 (1): 67-73
133. **Kröger N, Zander AR:** Dose and Schedule Effect of G-CSF for Stem Cell Mobilization in Healthy Donors for Allogeneic Transplantation. *Leukemia and Lymphoma* 2002; 43 (7): 1391-1394
134. **Kröger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuk F, Wittkowsky G, Schmitz N, Zander AR:** Unrelated stem cell transplantation in multiple myeloma after a reduced intensity conditioning with pretransplant anti-thymocyte globulin is highly effective with low transplantation related mortality. *Blood* 2002; 100: 3919-3924
135. **Kröger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, Fehse B, Tögel F, Wittkowsky G, Kuse R, and Zander AR:** Autologous stem cell transplatation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. *Blood* 2002; 100: 755-760

136. **Kröger N, Zabelina Z, Krüger W, Renges H, Stute N, Rischewski J, Sonnenberg S, Ayuk F, Tögel F, Schade U, Fiegel H, Erttmann R, Löliger C, and Zander AR:** *In vivo* T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. *Bone Marrow Transplantation* 2002; 29: 683-689
137. **Kröger N, Renges H, Sonnenberg S, Krüger W, Gutensohn K, Dielschneider T, Cortes-Dericks L, Zander AR:** Stem cell mobilisation with 16 µg/kg vs 10 µg/kg of G-CSF for allogeneic transplantation in healthy donors. *Bone Marrow Transplantation* 2002; 29(9): 727-730

2001

138. **Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Dürken M, von Finckenstein F, Erttmann R, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Zander AR.** Anti-Thymocyte-Globulin as part of the preparative regimen prevents acute and chronic Graft versus Host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. *Annals of Hematology* 2001; 80 (4): 209-215
139. **Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Kabisch H, Jaburg N, Löliger C, Krüll A, Zander AR.** Comparison between total body irradiation versus busulfan in combination with cyclophosphamide as conditioning regimen for unrelated stem cell transplantation in CML patients. *Bone Marrow Transplantation* 2001; 27 (4): 349-54
140. **Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Schafhausen P, Jaburg N, Löliger C, Schäfer P, Hinke A, Zander AR.** CMV-seropositivity of the patient with or without reactivation is the most important prognostic factor for survival and treatment related mortality in stem cell transplantation from unrelated donors using pretransplant in-vivo T-cell depletion with ATG. *British Journal of Haematology* 2001; 113 (4): 1060-1071
141. **Kröger N, Krüger W, Renges W, Zabelina T, Stute N, Jung R, Wittkowsky G, Kuse R, Zander AR.** Donor Lymphocyte Infusion enhances Remission Status in Patients with persistent Disease after Allografting for Multiple Myeloma. *British Journal of Haematology* 2001; 112:421-23.
142. **Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR:** A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. *Bone Marrow Transplant* 2001; 28 (7): 643-7

2000

143. **Kröger N, Hoffknecht M, Krüger W, Zeller W, Renges H, Stute N, Zschaber R, Zander AR.** Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. *Annals of Hematology* 2000; 79: 780-780.
144. **Kröger N, Renges H, Krüger W, Gutensohn K, Löliger C, Carrero I, Cortes L, Zander AR.** A randomized comparison of once versus twice daily rh-G-CSF (Filgrastim) for stem cell mobilisation in healthy donors for allogeneic transplantation. *British Journal of Haematology* 2000; 111: 761-765.
145. **Kröger N, Krüger W, Renges H, Zeller W, Rauhöft C, Löliger C, Zander AR.** Comparison of progenitor cell collection on day 4 or day 5 after steady-state stimulation with G-CSF alone in breast cancer patients: Influence on CD34+ cell yield, subpopulation and tumor cell contamination. *Journal of Hematotherapy and Stem cell research* 2000; 9: 111-117.
146. **Kröger N, Kleeberg UR, Mross K, Edler L, Saß G, Hossfeld DK.** Phase II Clinical trial of Titanocene-dichloride in patients with metastatic breast cancer. *Onkologie* 2000; 23: 60-62.
147. **Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finckenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.** Dose-dependent Effect of Etoposide in Combination with Busulfan plus Cyclophosphamide as Conditioning Regimen for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. *Bone Marrow Transplantation* 2000; 26: 711-716.

1999

148. Kröger N, Zeller W, Hassan HT, Krüger W, Renges H, Rüssmann B, Fuchs N, Hummel K, Rauhöft C, Gutensohn K, Lölliger C, Erttmann R, Kühnl P, Zander AR: Steady-state mobilization of peripheral blood progenitor cells by cytokines alone in patients with solid tumors or hematological malignancies. *Infusion Therapy and Transfusion Medicine* 1999; 26: 85-90.
149. Kröger N, Zeller W, Hassan HT, Krüger W, Gutensohn K, Lölliger C, Zander AR. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2x5µg/kg) compared to single dose (1x10µg/kg). *Bone Marrow Transplantation* 1999; 23: 125-129.
150. Kröger N, Rauhöft C, Krüger W, Zeller W, Renges H, Hassan HT, Schuch G, Wacker-Backhaus G, Colberg H, Kuse R, Gutensohn K, Lölliger C, Zander AR. Efficacy of further attempts to mobilize CD34+ peripheral stem cells with alternative procedures after primary failure. *Acta Haematologica* 1999; 102: 144-147.
151. Kröger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR. Current options in treatment of anthracycline-resistant breast cancer. *Cancer Treatment Review* 1999; 25: 279-291.

1998

152. Kröger N, Zeller W, Hassan HT, Dierlamm J, Zander AR. Difference between expression of adhesion-molecules on CD34+ cells from bone marrow and G-CSF stimulated peripheral blood. *Stem Cells* 1998; 16: 49-53.
153. Kröger N, Hoffknecht M, Dreger P, Krüger W, Zeller W, Krüll A, Stockschräder M, Bittner S, Weh HJ, Zander AR. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. *Bone Marrow Transplantation* 1998; 21: 55-57.
154. Kröger N, Zeller W, Hassan HT, Krüger W, Renges H, Hummel K, Gutensohn K, Lölliger C, Zander AR. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. *Ann Hematol* 1998; 76: 257-262.
155. Kröger N, Hoffknecht M, Hänel M, Krüger W, Zeller W, Stockschräder M, de Wit M, Weh HJ, Kabisch H, Erttmann R, Zander AR. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. *Bone Marrow Transplantation* 1998; 21: 1171-1175.
156. Kröger N, Krüger W, Zander AR. Hochdosischemotherapie beim Mammakarzinom. *Kliniker* 1998; 6/27: 155-160.
157. Kröger N, Zeller W, Fehse N, Hassan HT, Krüger W, Gutensohn K, Lölliger C, Zander AR. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexamethasone-BEAM plus G-CSF in lymphoma patients. *British Journal of Haematology* 1998; 102: 1101-1106.
158. Kröger N, Krüger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschräder M, Fuchs N, Rüssmann B, Renges H, Dürken M, Bielack S, de Wit M, Schuch G, Bartels H, Braumann D, Kuse R, Kabisch H, Erttmann R, Zander AR. Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia. *Bone Marrow Transplantation* 1998; 21: 1029-33.
159. Kröger N, Frick M, Nitz U, Zander AR. Ongoing prospective, randomized trial of single versus Tandem High-dose chemotherapy (CTC) in patients with metastatic breast cancer responding to conventional chemotherapy with partial or complete remission. *Bone Marrow Transplantation* 1998; 22 (Suppl 2): 14-15.
160. Kröger N, Zeller W, Hassan HT, Krüger W, Lölliger C, Zander AR. Schedule dependency of granulocyte colony stimulating factor in peripheral blood progenitor cell mobilisation in breast cancer patients. *Blood* 1998; 91:1828-9.

1996 und älter

161. Kröger N, Zschaber R, Hossfeld DK: Taxane in der Onkologie. *Hamburger Ärzteblatt* 1996; 2: 60-63.
162. Kröger N, Zschaber R, Krüger W, Mross K, Zander AR, Hossfeld DK: Dose-intensity of Chemotherapy in Breast Cancer. *Onkologie* 1995; 18: 419-28.

163. **Kröger N, Buhl C, Pompecki R, Szuba J, Riebold M, Fibbe C:** Adultes Still-Syndrom. *Med Klinik* 1995; 89: 374-377.
164. **Kröger N, Frenzel H:** Diuretikaresistenz bei kongestiver Herzinsuffizienz. *Dtsch Med Wschr* 1993; 11 (118): 383-389.
165. **Kröger N, Szuba J, Frenzel H:** Metolazone in der Behandlung fortgeschrittener therapieresistenter dilatativer Kardiomyopathie. *Med. Klinik* 1991; 86 (6): 305-308.
166. **Kröger N, Szuba J, Buhl C, Frenzel H:** Metolazone for severe dilated cardiomyopathy refractory to conventional therapy. *Lancet* 1990; Apr. 28: 1031-32.
167. **Kröger N:** Computergestützte zytomorphometrische Analyse von Speicheldrüsentumoren und verwandter Gewebe. *Dissertation Universität Hamburg* 1989

2015

168. Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kröger N, Platzbecker U, Stadler M, de Haas K, Altamura S, Muckenthaler MU, Niederwieser D, Al-Ali HK. *Bone Marrow Transplant.* 2015 Sept 14 [Epub ahead of print]
169. Klyuchnikov E, Bacher U, Kröger N, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-intensity allografting as first transplantation approach in relapsed/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors. *Biol Blood Marrow Transplant.* 2015 Aug 4 [Epub ahead of print]
170. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C; ESMO Guidelines Committee. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. *Ann Oncol.* 2015;26 Suppl 5:v85-v99.
171. Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Polge E, Aljurf M, Kröger N, Craddock C, Bacigalupo A, Cornelissen JJ, Baron F, Unger R, Nagler A, Mohty M. Prediction of allogeneic hematopoietic stem cell transplantation mortality 100 days after transplantation using a machine learning algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party retrospective data mining study. *J Clin Oncol.* 2015 Aug 3 [Epub ahead of print]
172. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. *Leukemia.* 2015 Jul 31. doi: 10.1038/leu.2015.212. [Epub ahead of print]
173. Yousef S, Heise J, Lajmi N, Bartels K, Kröger N, Luetkens T, Atanackovic D. Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. *J Transl Med.* 2015 Jun 20;13:197.
174. Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwai N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. *Hum Vaccin Immunother.* 2015;11(7):1606-11.
175. Stellmann JP, Stürner KH, Ufer F, Havemeister S, Pöttgen J, Ayuk Ayuketang F, Kröger N, Friese MA, Heesen C. Stem cell transplantation for multiple sclerosis: Hamburg experiences and state of international research. *Nervenarzt.* 2015;86(8):989-96.
176. Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, Veelken H, Milpied N, Van Gelder M, Peffault de Latour R, Gluckman E, Kröger N, Schetelig J, Rocha V. Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Party(CMWP) of the EBMT and the Société Française de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). *Biol Blood Marrow Transplant.* 2015;21(8):1515-23.
177. Parampalli Yajnanarayana S, Stübiger T, Cornez I, Alchalby H, Schönberg K, Rudolph J, Trivai I, Wolschke C, Heine A, Brossart P, Kröger N, Wolf D. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. *Br J Haematol.* 2015;169(6):824-833.

178. **Sahebi F, Iacobelli S, Biezen AV, Volin L, Dreger P, Michallet M, Ljungman PT, de Witte T, Henseler A, Schaap NP, López-Corral L, Poire X, Passweg J, Hamljadi RM, Thomas SH, Schonland S, Gahrton G, Morris C, Kröger N, Garderet L.** Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma. *Bone Marrow Transplant.* 2015;50(6):802-7.
179. **Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh JC, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A.** Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. *Bone Marrow Transplant.* 2015;50(8):1037-56.
180. **Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E;** Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? *Biol Blood Marrow Transplant.* 2015;21(7):1230-6.
181. **Stahl T, Böhme MU, Kröger N, Fehse B.** Digital PCR to assess hematopoietic chimerism after allogeneic stem cell transplantation. *Exp Hematol.* 2015;43(6):462-8.
182. **van der Torren CR, van Hensbergen Y, Luther S, Aghai Z, Rychnavská ZS, Slot M, Scherjon S, Kröger N, Ganser A, Weissinger EM, Goulmy E, Hambach L.** Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission. *PLoS One.* 2015 Mar 16;10(3):e0119595. doi: 10.1371/journal.pone.0119595. eCollection 2015.
183. **Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Kröger N, Luetkens T, Atanackovic D.** Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. *Blood Cancer J.* 2015 Mar 6;5:e285. doi: 10.1038/bcj.2015.7. No abstract available.
184. **Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, Potter M, Schattenberg AV, Cornelissen JJ, Hamljadi RM, Martelli M, Petersen E, Rovira M, Bandini G, Kroger N, de Witte T.** Efficacy and Outcome of Allogeneic Transplantation in IgD and Nonsecretory Myeloma. A Report on Behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2015 Jun;21(6):1054-8. doi: 10.1016/j.bbmt.2015.02.012. Epub 2015 Feb 20.
185. **Derlin T, Laqmani A, Veldhoen S, Apostolova I, Ayuk F, Adam G, Kröger N, Bannas P.** Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation. *Eur Radiol.* 2015 May;25(5):1229-37. doi: 10.1007/s00330-014-3503-4. Epub 2014 Nov 23.
186. **Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M.** Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. *Bone Marrow Transplant.* 2015 Apr;50(4):476-82. doi: 10.1038/bmt.2014.312. Epub 2015 Feb 2.
187. **Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G.** Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. *Bone Marrow Transplant.* 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26.
188. **Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann WK, Kröger N, Fiedler W, Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M.** Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. *Haematologica.* 2015 Apr;100(4):e122-4. doi: 10.3324/haematol.2014.120345. Epub 2014 Dec 31. No abstract available.

189. Schroeder T, Rachlis E, Bug G, Stelljes M, Klein S, Steckel NK, Wolf D, Ringhoffer M, Czibere A, Nachtkamp K, Dienst A, Kondakci M, Stadler M, Platzbecker U, Uharek L, Luft T, Fenk R, Germing U, Bornhäuser M, Kröger N, Beelen DW, Haas R, Kobbe G. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group. *Biol Blood Marrow Transplant*. 2015 Apr;21(4):653-60. doi: 10.1016/j.bbmt.2014.12.016. Epub 2014 Dec 23.
190. Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. *Haematologica*. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.
191. Basak GW, Wiktor-Jedrzejczak W, Labopin M, Schoemans H, Ljungman P, Kobbe G, Beguin Y, Lang P, Koenecke C, Sykora KW, Te Boome L, van Biezen A, van der Werf S, Mohty M, de Witte T, Marsh J, Dreger P, Kröger N, Duarte R, Ruutu T. Allogeneic hematopoietic stem cell transplantation in solid organ transplant recipients: a retrospective, multicenter study of the EBMT. *Am J Transplant*. 2015 Mar;15(3):705-14. doi: 10.1111/ajt.13017. Epub 2015 Feb 3.
192. Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. *Leukemia*. 2015 Mar;29(3):696-704. doi: 10.1038/leu.2014.236. Epub 2014 Aug 8.
193. Ballinger TJ, Savani BN, Gupta V, Kroger N, Mohty M. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. *Eur J Haematol*. 2015 Feb;94(2):115-9. doi: 10.1111/ejh.12455. Epub 2014 Nov 21.
194. Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, Trivai I, Alchalby H, Kröger N, Kreipe H. SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. *Leukemia*. 2015 Jan;29(1):253-5. doi: 10.1038/leu.2014.277. Epub 2014 Sep 18. No abstract available.
195. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). *Leukemia*. 2015 Jan;29(1):20-6. doi: 10.1038/leu.2014.250. Epub 2014 Aug 25. Review.

2014

196. Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. *Cancer Immunol Immunother*. 2014 Nov;63(11):1151-62. doi: 10.1007/s00262-014-1588-x. Epub 2014 Jul 31.
197. Onida F, Brand R, van Biezen A, Schaap M, von dem Borne PA, Maertens J, Beelen DW, Carreras E, Alessandrino EP, Volin L, Kuball JH, Figuera A, Sierra J, Finke J, Kröger N, de Witte T; MDS subcommittee of the EBMT-CMWP. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. *Haematologica*. 2014 Oct;99(10):1582-90. doi: 10.3324/haematol.2014.106880. Epub 2014 Aug 1.

198. **Sarkar S, Scherwath A, Schirmer L, Schulz-Kindermann F, Neumann K, Kruse M, Dinkel A, Kunze S, Balck F, Kröger N, Koch U, Mehnert A.** Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. *Bone Marrow Transplant.* 2014 Sep;49(9):1217-22. doi: 10.1038/bmt.2014.139. Epub 2014 Jul 7.
199. **Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E;** Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. *Haematologica.* 2014 Sep;99(9):1492-8. doi: 10.3324/haematol.2013.100198. Epub 2014 Jul 4.
200. **Derlin T, Laqmani A, Veldhoen S, Apostolova I, Ayuk F, Adam G, Kröger N, Bannas P.** Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation. *Eur Radiol.* 2015 May;25(5):1229-37. doi: 10.1007/s00330-014-3503-4. Epub 2014 Nov 23.
201. **Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S.** Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. *Leukemia.* 2015 Mar;29(3):696-704. doi: 10.1038/leu.2014.236. Epub 2014 Aug 8.
202. **Ballinger TJ, Savani BN, Gupta V, Kroger N, Mohty M.** How we manage JAK inhibition in allogeneic transplantation for myelofibrosis. *Eur J Haematol.* 2015 Feb;94(2):115-9. doi: 10.1111/ejh.12455. Epub 2014 Nov 21.
203. **Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, Triviai I, Alchalby H, Kröger N, Kreipe H.** SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. *Leukemia.* 2015 Jan;29(1):253-5. doi: 10.1038/leu.2014.277. Epub 2014 Sep 18. No abstract available.
204. **Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Harrison C, Hehlmann R, Hermouet S, Kiladjian JJ, Kröger N, Mesa R, Mc Mullin MF, Pardanani A, Passamonti F, Samuelsson J, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tognoni G, Barbui T.** Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). *Leukemia.* 2015 Jan;29(1):20-6. doi: 10.1038/leu.2014.250. Epub 2014 Aug 25. Review.
205. **Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D.** Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. *Bone Marrow Transplant.* 2014 Feb;49(2):168-73. doi: 10.1038/bmt.2013.107. Epub 2013 Jul 29. Erratum in: *Bone Marrow Transplant.* 2014 Feb;49(2):319. Dosage error in article text.
206. **de Wreede LC, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden CE, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher GM, Herr W, Choquet S, Niederwieser DW, Sutton L, Kröger N, de Witte TM, Schetelig** On Behalf Of The Chronic Malignancies Working Party of the EBMT And The UK Medical Research Council J. Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study. *Am J Hematol.* 2014 Feb;89(2):174-80. doi: 10.1002/ajh.23610.
207. **Lehmsberg K, Albert MH, Beier R, Beutel K, Gruhn B, Kröger N, Meisel R, Schulz A, Stachel D, Woessmann W, Janka G, Müller I.** Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. *Haematologica.* 2014 Jan;99(1):180-4. doi: 10.3324/haematol.2013.094730. Epub 2013 Oct 25.
208. **de Lima M, Porter DL, Battitwalla M, Bishop MR, Giralto SA, Hardy NM, Kröger N, Wayne AS, Schmid C.** Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation. *Biol Blood Marrow Transplant.* 2014 Jan;20(1):4-13. doi: 10.1016/j.bbmt.2013.08.012. Epub 2013 Sep 7.

209. **Avigan D, Hari P, Battiwalla M, Bishop MR, Giralto SA, Hardy NM, Kröger N, Wayne AS, Hsu KC.** Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part II. Autologous Transplantation-novel agents and immunomodulatory strategies. *Biol Blood Marrow Transplant.* 2013 Dec;19(12):1661-9. doi: 10.1016/j.bbmt.2013.08.011. Epub 2013 Sep 7.
210. **Wayne AS, Giralto S, Kröger N, Bishop MR.** Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction. *Biol Blood Marrow Transplant.* 2013 Nov;19(11):1534-6. doi: 10.1016/j.bbmt.2013.08.016. Epub 2013 Sep 10.
211. **Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralto SA, Hardy NM, Kröger N, Wayne AS, Landau DA, Wu CJ.** Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. *Biol Blood Marrow Transplant.* 2013 Nov;19(11):1537-45. doi: 10.1016/j.bbmt.2013.08.010. Epub 2013 Sep 6.
212. **Gerull S, Stern M, Apperley J, Beelen D, Brinch L, Bunjes D, Butler A, Ganzer A, Ghavamzadeh A, Koh MB, Komarnicki M, Kröger N, Maertens J, Maschan A, Peters C, Rovira M, Sengeløv H, Socié G, Tischer J, Oneto R, Passweg J, Marsh J.** Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation. *Haematologica.* 2013 Nov;98(11):1804-9. doi: 10.3324/haematol.2013.091074. Epub 2013 Jul 26.
213. **Schmidt-Hieber M, Labopin M, Beelen D, Volin L, Ehninger G, Finke J, Socié G, Schwerdtfeger R, Kröger N, Ganzer A, Niederwieser D, Polge E, Blau IW, Mohty M.** CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. *Blood.* 2013 Nov 7;122(19):3359-64. doi: 10.1182/blood-2013-05-499830. Epub 2013 Sep 13.
214. **Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Kade S, Löffeld P, Banihosseini S, Bug G, Ottmann O, Hofmann WK, Krauter J, Kröger N, Ganzer A, Heuser M.** SETBP1 mutation analysis in 944 patients with MDS and AML. *Leukemia.* 2013 Oct;27(10):2072-5. doi: 10.1038/leu.2013.145. Epub 2013 May 7. No abstract available.
215. **Lehmsberg K, Albert MH, Beier R, Beutel K, Gruhn B, Kröger N, Meisel R, Schulz A, Stachel D, Woessmann W, Janka G, Müller I.** Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis. *Haematologica.* 2013 Oct 25. [Epub ahead of print]
216. **de Wreede LC, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden CE, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher GM, Herr W, Choquet S, Niederwieser DW, Sutton L, Kröger N, de Witte TM, Schetelig J.** Improved PFS after autologous stem cell transplantation does not translate into better Quality of Life in CLL: lessons from the randomized EBMT-Intergroup study. *Am J Hematol.* 2013 Oct 9. doi: 10.1002/ajh.23610. [Epub ahead of print]
217. **Christopeit M, Kuss O, Finke J, Bacher U, Beelen DW, Bornhäuser M, Schwerdtfeger R, Bethge WA, Basara N, Gramatzki M, Tischer J, Kolb HJ, Uharek L, Meyer RG, Bunjes D, Scheid C, Martin H, Niederwieser D, Kröger N, Bertz H, Schrezenmeier H, Schmid C.** Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. *J Clin Oncol.* 2013 Sep 10;31(26):3259-71. doi: 10.1200/JCO.2012.44.7961. Epub 2013 Aug 5.
218. **Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Kröger N, Farge-Bancel D, Gaspar HB, Marsh J, Mohty M, Peters C, Sureda A, Velardi A, Ruiz de Elvira C, Madrigal A; European Group for Blood and Marrow Transplantation.** Hematopoietic SCT in Europe: data and trends in 2011. *Bone Marrow Transplant.* 2013 Sep;48(9):1161-7. doi: 10.1038/bmt.2013.51. Epub 2013 Apr 15.
219. **Christopeit M, Heiland A, Binder M, Zabelina T, Ayuk F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U.** Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML. *Bone Marrow Transplant.* 2013 Sep;48(9):1257-9. doi: 10.1038/bmt.2013.34. Epub 2013 Apr 8. No abstract available.

220. **Schroeder T, Fröbel J, Cadeddu RP, Czibere A, Dienst A, Platzbecker U, Bug G, Uharek L, Fenk R, Germing U, Kröger N, Haas R, Kobbe G.** Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. *Leukemia*. 2013 Sep;27(9):1910-3. doi: 10.1038/leu.2013.64. Epub 2013 Mar 1. No abstract available.
221. **Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G.** Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. *Blood*. 2013 Aug 22;122(8):1395-8. doi: 10.1182/blood-2013-03-488098. Epub 2013 Jul 9.
222. **Koch M, Gräser C, Lehnhardt A, Pollok JM, Kröger N, Verboom M, Thaiss F, Eiermann T, Nashan B.** Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib. *Transpl Int*. 2013 Aug;26(8):e64-8. doi: 10.1111/tri.12120. Epub 2013 May 15.
223. **Atanackovic D, Reinhard H, Meyer S, Spöck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Kröger N, Atz J, Seimetz D, Izbicki JR, Bokemeyer C.** The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. *Hum Vaccin Immunother*. 2013 Aug 16;9(12). [Epub ahead of print]
224. **Vater A, Sahlmann J, Kröger N, Zöllner S, Lioznov M, Maasch C, Buchner K, Vossmeier D, Schwoebel F, Purschke WG, Vonhoff S, Kruschinski A, Hübel K, Humphrey M, Klussmann S, Fliegert F.** Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. *Clin Pharmacol Ther*. 2013 Jul;94(1):150-7. doi: 10.1038/clpt.2013.58. Epub 2013 Mar 19.
225. **Atanackovic D, Nowotne U, Freier E, Weber CS, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kröger N, Brunner-Weinzierl MC, Bokemeyer C, Deter HC.** Acute psychological stress increases peripheral blood CD3+CD56+ natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders. *Stress*. 2013 Jul;16(4):421-8. doi: 10.3109/10253890.2013.777702. Epub 2013 Apr 8.
226. **Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D.** Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. *Bone Marrow Transplant*. 2013 Jul 29. doi: 10.1038/bmt.2013.107. [Epub ahead of print]
227. **Berdien B, Reinhard H, Meyer S, Spöck S, Kröger N, Atanackovic D, Fehse B.** Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy. *Hum Vaccin Immunother*. 2013 Jun;9(6):1205-16. doi: 10.4161/hv.24051. Epub 2013 Feb 21.
228. **Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G.** Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. *Leukemia*. 2013 Jun;27(6):1229-35. doi: 10.1038/leu.2013.7. Epub 2013 Jan 14.
229. **Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohty M;** Acute Leukemia Working Party the subcommittee for Myelodysplastic Syndromes of the Chronic Malignancies Working Party of the European group for Blood Marrow Transplantation Group (EBMT). Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. *Bone Marrow Transplant*. 2013 Jun;48(6):761-70. doi: 10.1038/bmt.2012.236. Epub 2012 Dec 3.
230. **Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann HH, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G.** Cytogenetics of extramedullary manifestations in multiple myeloma. *Br J Haematol*. 2013 Apr;161(1):87-94. doi: 10.1111/bjh.12223. Epub 2013 Feb 1.

231. **Langer F, Spath B, Fischer C, Stolz M, Ayuk FA, Kröger N, Bokemeyer C, Ruf W.** Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase. *Blood*. 2013 Mar 21;121(12):2324-35. doi: 10.1182/blood-2012-10-460493. Epub 2013 Jan 11.
232. **Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U.** Evaluation of BM cytomorphology after allo-SCT in patients with MDS. *Bone Marrow Transplant*. 2013 Mar;48(3):465-6. doi: 10.1038/bmt.2012.161. Epub 2012 Sep 3. No abstract available.
233. **Derlin T, Peldschus K, Münster S, Bannas P, Herrmann J, Stübig T, Habermann CR, Adam G, Kröger N, Weber C.** Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. *Eur Radiol*. 2013 Feb;23(2):570-8. doi: 10.1007/s00330-012-2600-5. Epub 2012 Jul 29.
234. **Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Sureda A, Mohty M, Dreger P; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties.** Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. *Blood*. 2013 Jan 17;121(3):440-6. doi: 10.1182/blood-2012-08-448613. Epub 2012 Nov 30.
235. **Bannas P, Kröger N, Adam G, Derlin T.** Modern imaging techniques in patients with multiple myeloma. *Rofo*. 2013 Jan;185(1):26-33. doi: 10.1055/s-0032-1325405. Epub 2012 Nov 29. Review. German.

2012

236. **Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kröger N, Bacher U.** Evaluation of BM cytomorphology after allo-SCT in patients with AML. *Bone Marrow Transplant*. 2012 Dec;47(12):1538-44. doi: 10.1038/bmt.2012.70. Epub 2012 Apr 30.
237. **Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D.** Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients. *Clin Dev Immunol*. 2012;2012:134081. doi: 10.1155/2012/134081. Epub 2012 Mar 12.
238. **Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I, Kanouni T, Bulabois CE, Tournilhac O, Buzyn A, Rio B, Moles MP, Shimoni A, Bacher U, Ocheni S, Milpied N, Harousseau JL, Moreau P, Leux C, Mohty M.** Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. *Ann Oncol*. 2012 Oct;23(10):2695-703. Epub 2012 Mar 22.
239. **Bornhäuser M, Kienast J, Trensche R, Burchert A, Hegenbart U, Stadler M, Baurmann H, Schäfer-Eckart K, Holler E, Kröger N, Schmid C, Einsele H, Kiehl MG, Hiddemann W, Schwerdtfeger R, Buchholz S, Dreger P, Neubauer A, Berdel WE, Ehninger G, Beelen DW, Schetelig J, Stelljes M.** Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. *Lancet Oncol*. 2012 Oct;13(10):1035-44. doi: 10.1016/S1470-2045(12)70349-2. Epub 2012 Sep 7.
240. **Bannas P, Hentschel HB, Bley TA, Treszl A, Eulenburg C, Derlin T, Yamamura J, Adam G, Stübig T, Kröger N, Weber C.** Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. *Eur Radiol*. 2012 Sep;22(9):2007-12. doi: 10.1007/s00330-012-2445-y. Epub 2012 Apr 29.
241. **Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Gerald C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF.** European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. *Bone Marrow Transplant*. 2012 Aug;47(8):1046-50. doi: 10.1038/bmt.2011.216. Epub 2011 Nov 14.

242. **Billecke L, Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G.** Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma. *Anticancer Res.* 2012 May;32(5):2031-4.
243. **Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M;** Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. *Blood.* 2012 Feb 9;119(6):1599-606. doi: 10.1182/blood-2011-08-375840. Epub 2011 Dec 13.
244. **Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Gheraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF.** Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. *Biol Blood Marrow Transplant.* 2012 Feb;18(2):314-7. doi: 10.1016/j.bbmt.2011.10.003. Epub 2011 Oct 13.
245. **Schroeder T, Kuendgen A, Kayser S, Kröger N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler M, Schlenk R, Czibere AG, Bruns I, Fenk R, Gattermann N, Haas R, Kobbe G, Germing U.** Therapy-related myeloid neoplasms following treatment with radioiodine. *Haematologica.* 2012 Feb;97(2):206-12. doi: 10.3324/haematol.2011.049114. Epub 2011 Oct 11.
246. **Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Kröger N, Atanackovic D.** Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients. *Clin Dev Immunol.* 2012;2012:134081. Epub 2012 Mar 12.

2011

247. **Langebrake C, Bernhardt F, Baehr M, Kröger N, Zander AR.** Drug dosing and monitoring in obese patients undergoing allogeneic stem cell transplantation. *Int J Clin Pharm.* 2011 Dec;33(6):918-24. Epub 2011 Sep 29.
248. **Duske H, Sputtek A, Binder T, Kröger N, Schrepfer S, Eiermann T.** Assessment of physiologic natural killer cell cytotoxicity in vitro. *Hum Immunol.* 2011 Nov;72(11):1007-12. Epub 2011 Aug 10.
249. **Oyekunle A, Haferlach T, Kröger N, Klyuchnikov E, Zander AR, Schnittger S, Bacher U.** Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia. *Adv Hematol.* 2011;2011:154745. Epub 2011 Nov 10.
250. **Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Kröger N, Atanackovic D.** Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. *Clin Dev Immunol.* 2011;2011:302145. Epub 2011 Nov 15.
251. **Peinemann F, Grouven U, Kröger N, Bartel C, Pittler MH, Lange S.** First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. *PLoS One.* 2011 Apr 25;6(4):e18572.
252. **Bishop MR, Alyea EP 3rd, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giral S.** National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. *Biol Blood Marrow Transplant.* 2011 Apr;17(4):443-54. Epub 2011 Jan 9.
253. **Sputtek A, Lioznov M, Kröger N, Rowe AW.** Bioequivalence comparison of a new freezing bag (CryoMACS®) with the Cryocyte® freezing bag for cryogenic storage of human hematopoietic progenitor cells. *Cytotherapy.* 2011 Apr;13(4):481-9. Epub 2010 Nov 15.
254. **Oyekunle A, Klyuchnikov E, Ocheni S, Kröger N, Zander AR, Baccarani M, Bacher U.** Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. *Acta Haematol.* 2011;126(1):30-9. doi: 10.1159/000323662. Epub 2011 Mar 17.
255. **Peinemann F, Kröger N, Bartel C, Grouven U, Pittler M, Erttmann R, Kulig M.** High-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma--a systematic review. *PLoS One.* 2011 Feb 23;6(2):e17127.

256. **Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjan JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet.** Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *J Clin Oncol.* 2011 Feb 20;29(6):761-70. Epub 2011 Jan 4.
257. **Peinemann F, Smith LA, Kromp M, Bartel C, Kröger N, Kulig M.** Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas. *Cochrane Database Syst Rev.* 2011 Feb 16;(2):CD008216. Review. PubMed PMID: 21328307.
258. **Ocheni S, Oyekunle A, Kröger N, Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjallé R, Wolschke C, Zander AR, Bacher U.** Second allogeneic stem cell transplantation in a patient with hypoplastic myelodysplastic syndrome following a primary diagnosis of aplastic anaemia. *Acta Haematol.* 2011;125(3):175-8. Epub 2010 Dec 30.
259. **Klyuchnikov E, Bacher U, Kröger N, Kazantsev I, Zabelina T, Ayuk F, Zander AR.** The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients. *Adv Hematol.* 2011;2011:974658. Epub 2010 Oct 26.
260. **Muth M, Engelhardt BM, Kröger N, Hussein K, Schlué J, Büsche G, Kreipe HH, Bock O.** Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) – a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia. *Ann Hematol.* 2011 Jan;90(1):33-40. Epub 2010 Jul 13.
261. **Robin M, Sanz GF, Ionescu I, Rio B, Sirvent A, Renaud M, Carreras E, Milpied N, Mohty M, Beguin Y, Bordigoni P, de Witte T, Picardi A, Purtill D, Gluckman E, Kröger N, Rocha V.** Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. *Leukemia.* 2011 Jan;25(1):75-81. Epub 2010 Sep 30.
262. **Lellek H, Waldenmaier D, Dahlke J, Ayuk FA, Wolschke C, Kröger N, Zander AR.** Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. *Mycoses.* 2011 Jan;54 Suppl 1:39-44. doi: 10.1111/j.1439-0507.2010.01985.x.

2010

263. **Ocheni S, Oyekunle A, Kröger N, Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjallé R, Wolschke C, Zander AR, Bacher U.** Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia. *Acta Haematol.* 2010 Dec 30;125(3):175-178.
264. **Bacher U, Haferlach T, Alpermann T, Zenger M, Kröger N, Beelen DW, Kern W, Schnittger S, Haferlach C.** Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. *Biol Blood Marrow Transplant.* 2010 Dec;16(12):1649-57.
265. **Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander AR, Bacher U.** Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia. *Exp Hematol.* 2010 Dec;38(12):1261-71.
266. **Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels BM, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brümmendorf TH, Atanackovic D.** Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. *Leuk Res.* 2010 Dec;34(12):1647-55.
267. **Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kröger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K.** NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2010 Nov;16(11):1467-503.
268. **Sputtek A, Lioznov M, Kröger N, Rowe AW.** Bioequivalence comparison of a new freezing bag (CryoMACS®) with the Cryocyte® freezing bag for cryogenic storage of human hematopoietic progenitor cells. *Cytotherapy.* 2010 Nov 15.

269. **Hambach L, Aghai Z, Pool J, Kröger N, Goulmy E.** Peptide length extension skews the minor HA-1 antigen presentation toward activated dendritic cells but reduces its presentation efficiency. *J Immunol.* 2010 Oct 15;185(8):4582-9.
270. **Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simon JA, Kröger N, Moreau P, Gahrton G, Gasparetto C, Giralt S, Bensinger W.** International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. *J Clin Oncol.* 2010 Oct 10;28(29):4521-30.
271. **Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander AR, Bokemeyer C, Kröger N, Atanackovic D.** The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. *Exp Hematol.* 2010 Oct;38(10):860-7. Epub 2010 Jul 7.
272. **Pabst C, Zustin J, Jacobsen F, Luetkens T, Kröger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A.** Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. *Exp Mol Pathol.* 2010 Oct;89(2):175-81. Epub 2010 Jul 14.
273. **Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuk F, Zander AR, Fehse B, Bacher U.** Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. *Leuk Lymphoma.* 2010 Oct;51(10):1837-43.
274. **Bacher U, Asenova S, Badbaran A, Zander AR, Alchalby H, Fehse B, Kröger N, Lange C, Ayuk F.** Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. *Clin Exp Med.* 2010 Sep;10(3):205-8. Epub 2009 Jul 23.
275. **Koenecke C, Hertenstein B, Schetelig J, van Biezen A, Dammann E, Gratwohl A, Ganser A, Schleuning M, Bornhäuser M, Jacobsen N, Kröger N, Niederwieser D, de Witte T, Ruutu T.** Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: a retrospective, multicenter study of the EBMT. *Am J Transplant.* 2010 Aug;10(8):1897-906.
276. **Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander AR, Kröger N, Nagler A.** Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. *Cancer.* 2010 Aug 1;116(15):3621-30.
277. **Cavattoni I, Ayuk F, Zander AR, Zabelina T, Bacher A, Cayroglu E, Knospe V, Illies T, Aepfelbacher M, Richard G, Kröger N, Bacher U.** Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny. *Leuk Lymphoma.* 2010 Aug;51(8):1530-5.
278. **Klyuchnikov E, Asenova S, Kern W, Kilinc G, Ayuk F, Wiedemann B, Lioznov M, Freiburger P, Zalyalov Y, Zander AR, Kröger N, Bacher U.** Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia. *Leuk Lymphoma.* 2010 Aug;51(8):1450-63.
279. **Casper J, Wolff D, Knauf W, Blau IW, Ruutu T, Volin L, Wandt H, Schäfer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander AR, Kröger N, Hilgendorf I, Baumgart J, Mylius HA, Pichlmeier U, Freund M.** Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. *J Clin Oncol.* 2010 Jul 10;28(20):3344-51. Erratum in: *J Clin Oncol.* 2010 Aug 10;28(23):3797.
280. **Carreras E, Cahn JY, Puozzo C, Kröger N, Sanz G, Buzyn A, Bacigalupo A, Vernant JP.** Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. *Anticancer Res.* 2010 Jul;30(7):2977-84. Erratum in: *Anticancer Res.* 2010 Sep;30(9):3851. Dosage error in article text.
281. **Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, Hildebrandt Y, Luetkens T, Ihloff AS, Kröger N, Bokemeyer C, Atanackovic D.** An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body. *J Immunol Methods.* 2010 Jun 30;358(1-2):56-65. Epub 2010 Mar.17.

282. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*. 2010 Jun;24(6):1121-7. Review.
283. Bishop MR, Alyea EP 3rd, Cairo MS, Falkenburg JH, June CH, Kröger N, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giral S. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2010 May;16(5):563-4.
284. Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. *Bone Marrow Transplant*. 2010 May;45(5):872-6.
285. Wüsthof M, Smirnova A, Bacher U, Kröger N, Zander AR, Schuch G, Bokemeyer C. Severe aplastic anaemia following leflunomide therapy. *Rheumatology (Oxford)*. 2010 May;49(5):1016-7.
286. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giral SA, Arora M. Outcome of transplantation for myelofibrosis. *Biol Blood Marrow Transplant*. 2010 Mar;16(3):358-67.
287. Klyuchnikov E, Kröger N, Brummendorf TH, Wiedemann B, Zander AR, Bacher U. Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML). *Biol Blood Marrow Transplant*. 2010 Mar;16(3):301-10.
288. Lim Z, Brand R, Martino R, van Biezen A, Finke J, Bacigalupo A, Beelen D, Devergie A, Alessandrino E, Willemze R, Ruutu T, Boogaerts M, Falda M, Jouet JP, Niederwieser D, Kröger N, Mufti GJ, De Witte TM. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. *J Clin Oncol*. 2010 Jan 20;28(3):405-11.
289. Neth OW, Bacher U, Das P, Zabelina T, Kabisch H, Kröger N, Ayuk F, Lioznov M, Waschke O, Fehse B, Thiébaud R, Haston RM, Klein N, Zander AR. Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors. *Bone Marrow Transplant*. 2010 Jan;45(1):13-9.
290. Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels BM, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Kröger N, Bokemeyer C, Brummendorf TH, Atanackovic D. Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. *Leuk Res*. 2010 Apr 19.
291. Neth OW, Bacher U, Das P, Zabelina T, Kabisch H, Kröger N, Ayuk F, Lioznov M, Waschke O, Fehse B, Thiébaud R, Haston RM, Klein N, Zander AR. Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors. *Bone Marrow Transplant*. 2010 Jan;45(1):13-9.
292. Bacher U, Haferlach C, Kröger N, Schnittger S, Kern W, Wiedemann B, Zander AR, Haferlach T. Diagnostic tools in the indications for allogeneic stem cell transplantation in myelodysplastic syndromes. *Biol Blood Marrow Transplant*. 2010 Jan;16(1):1-11.

2009

293. Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander AR, Bacher U. Second allogeneic stem cell transplantation in myeloid malignancies. *Acta Haematol*. 2009;122(4):185-92.
294. Bacher U, Asenova S, Badbaran A, Zander AR, Alchalby H, Fehse B, Kröger N, Lange C, Ayuk F. Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. *Clin Exp Med*. 2009 Jul 23.

295. Klyuchnikov E, Schafhausen P, Kröger N, Brummendorf TH, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuk F, Zander AR, Bacher U. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. *Acta Haematol.* 2009;122(1):6-10.
296. Ocheni S, Iwanski GB, Schafhausen P, Zander AR, Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brummendorf TH, Kröger N, Bacher U. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. *Leuk Lymphoma.* 2009 Apr;50(4):551-8.
297. Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H, Ehninger G, Müller C, Berger J, Suttrop M, Kolb HJ, Kröger N, Zander AR. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia--a report from the German Registry covering the period from 1998 to 2004. *Ann Hematol.* 2009 Dec;88(12):1237-47.
298. Perz JB, Hegenbart U, Kröger N, Otto G, Ho AD, Dreger P. Successful unrelated donor stem cell transplantation for advanced myelofibrosis in an adult patient with history of orthotopic liver transplantation. *Haematologica.* 2009 Feb 19.
299. Gupta V, Kröger N, Aschan J, Xu W, Leber B, Dalley C, Sabloff M, Lipton JH, Messner H, Brune M. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. *Bone Marrow Transplant.* 2009 Feb 23.
300. Hussein K, Bock O, Theophile K, Schlue J, Ballmaier M, Kröger N, Göhring G, Büsche G, Kreipe H. Biclonal expansion and heterogeneous lineage involvement in a case of chronic myeloproliferative disease with concurrent MPLW515L/JAK2V617F mutation. *Blood.* 2009 Feb 5;113(6):1391-2.
301. Schonland SO, Kröger N, Wolschke C, Dreger P, Ho AD, Hegenbart U. Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect". *Haematologica.* 2009 Mar;94(3):439-41.
302. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harivel V, Marzac C, Pietra D, Sobas M, Mounier M, Migeon M, Ellard S, Kröger N, Herrmann R, Prchal JT, Skoda RC, Hermouet S. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. *Haematologica.* 2009 Jan;94(1):38-45.

2008

303. Ocheni S, Kröger N, Zabelina T, Zander AR, Bacher U. Outcome of allo-SCT for chronic myelomonocytic leukemia. *Bone Marrow Transplant.* 2008 Nov 10.
304. Platzbecker U, Bornhäuser M, Germing U, Stumpf J, Scott BL, Kröger N, Schwerdtfeger R, Böhm A, Kobbe G, Theuser C, Rabitsch W, Valent P, Sorrow ML, Ehninger G, Deeg HJ. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). *Biol Blood Marrow Transplant.* 2008 Nov;14(11):1217-25.
305. Benjamini O, Koren-Michowitz M, Amariglio N, Kröger N, Nagler A, Shimoni A. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. *Leukemia.* 2008 Oct;22(10):1961-3.
306. Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kröger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. *Br J Cancer.* 2008 Sep 16;99(6):930-8.
307. Kluge S, Baumann HJ, Nierhaus A, Kröger N, Meyer A, Kreymann G. Safety of percutaneous dilational tracheostomy in hematopoietic stem cell transplantation recipients requiring long-term mechanical ventilation. *J Crit Care.* 2008 Sep;23(3):394-8.
308. Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander AR. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation. *Biol Blood Marrow Transplant.* 2008 Aug;14(8):913-9.
309. Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander AR. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. *Exp Hematol.* 2008 Aug;36(8):1047-54.

310. **Lioznov M, Dellbrügger C, Sputtek A, Fehse B, Kröger N, Zander AR.** Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM. *Bone Marrow Transplant.* 2008 Jul;42(2):121-8.
311. **Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W.** Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. *Ann Oncol.* 2008 Jun;19(6):1082-9.
312. **Siebolts U, Thiele J, Zander T, Ditschkowski M, Beelen DW, Kröger N, Fehse B, Wickenhauser C.** Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF. *Oncol Rep.* 2008 Jan;19(1):287-92.

2007

313. **Gahrton G, Iacobelli S, Bandini G, Björkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland SO, Verdonck LF, Volin L, de Witte T, Niederwieser D; Myeloma Subcommittee of the EBMT.** Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. *Haematologica.* 2007 Nov;92(11):1513-8.
314. **Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, Dechow T, Kröger N, Salwender H, Metzner B, Sezer O, Engelhardt M, Wolf HH, Einsele H, Volpert S, Heinecke A, Berdel WE, Kienast J; Deutsche Studiengruppe Multiples Myelom.** Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. *Br J Haematol.* 2007 Aug;138(3):330-7.

2006

315. **de Witte T, Brand R, van Biezen A, Delforge M, Biersack H, Or R, Meloni G, Bandini B, Sierra J, Kröger N, Gratwohl A, Niederwieser D.** The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. *Haematologica.* 2006 Jun;91(6):750-6.
316. **van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM.** Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. *Bone Marrow Transplant.* 2006 Jun;37(12):1135-41.
317. **Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti GJ, Kröger N, Zander AR, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, Lopez-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter AE, Marr KA, Dornbusch HJ, Einsele H.** Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Blood.* 2006 Nov 1;108(9):2928-36.
318. **van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM.** Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. *Blood.* 2006 Apr 15;107(8):3415-6.
319. **Einsele H, Reusser P, Bornhäuser M, Kalhs P, Ehninger G, Hebart H, Chalandon Y, Kröger N, Hertenstein B, Rohde F.** Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. *Blood.* 2006 Apr 1;107(7):3002-8.
320. **Gutensohn K, Magens M, Krüger W, Kröger N, Kühnl P.** Comparison of flow cytometry vs. a haematology cell analyser-based method to guide the optimal time-point for peripheral blood stem cell apheresis. *Vox Sang.* 2006 Jan;90(1):53-8.

321. **Bornhäuser M, Kröger N, Schwerdtfeger R, Schäfer-Eckart K, Sayer HG, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR; Cooperative German Transplant Study Group.** Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. *Eur J Haematol.* 2006 Jan;76(1):9-17.
322. **Schonland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, Campbell A, Carreras E, Ferrant A, Grommisch L, Jacobs P, Kröger N, La Nasa G, Russell N, Zachee P, Goldschmidt H, Iacobelli S, Niederwieser D, Gahrton G; Chronic Leukemia Working Party; Myeloma Subcommittee of the European Cooperative Group for Blood and Marrow Transplantation.** Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. *Blood.* 2006 Mar 15;107(6):2578-84.
323. **Oyekunle AA, Kröger N, Zabelina T, Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander AR.** Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up. *Bone Marrow Transplant.* 2006 Jan;37(1):45-50.
324. **Dahlke J, Kröger N, Zabelina T, Ayuk F, Fehse N, Wolschke C, Waschke O, Schieder H, Renges H, Krüger W, Kruell A, Hinke A, Erttmann R, Kabisch H, Zander AR.** Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. *Bone Marrow Transplant.* 2006 Jan;37(2):155-63.

2005

325. **Schetelig J, Breitschaft A, Kröger N, Zabelina T, Ebell W, Bornhäuser M, Haack A, Ehninger G, Salama A, Siegert W; Cooperative Transplantations Study Group.** After major ABO-mismatched allogeneic hematopoietic progenitor cell transplantation, erythroid engraftment occurs later in patients with donor blood group A than donor blood group B. *Transfusion.* 2005 May;45(5):779-87.
326. **Zander AR, Kröger N.** High-dose therapy for breast cancer - a case of suspended animation. *Acta Haematol.* 2005;114(4):248-54.
327. **Lioznov MV, Freiburger P, Kröger N, Zander AR, Fehse B.** Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants. *Bone Marrow Transplant.* 2005 May;35(9):909-14.
328. **Krüger WH, Russmann B, de Wit M, Kröger N, Renges H, Sobottka I, Zander AR.** Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. *Acta Haematol.* 2005;113(2):104-8.
329. **Gahrton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Bladé J, Boiron JM, Cavo M, Cornelissen J, Corradini P, Kröger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D.** The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. *Bone Marrow Transplant.* 2005 Mar;35(6):609-17.
330. **Shimoni A, Kröger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander AR, Nagler A.** Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. *Leukemia.* 2005 Jan;19(1):7-12.

2004

331. **Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kröger N, Stelljes M, Bornhäuser M, Martin H, Scheid C, Ganser A, Zander AR, Kienast J, Ehninger G, Hoelzer D, Diehl V, Fauser AA, Ringden O.** Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. *J Clin Oncol.* 2004 Jul 15;22(14):2816-25.
332. **Rohde H, Kalitzky M, Kröger N, Scherpe S, Horstkotte MA, Knobloch JK, Zander AR, Mack D.** Detection of virulence-associated genes not useful for discriminating between invasive and commensal *Staphylococcus epidermidis* strains from a bone marrow transplant unit. *J Clin Microbiol.* 2004 Dec;42(12):5614-9.

333. Casper J, Knauf W, Blau I, Ruutu T, Volin L, Wandt H, Schafer-Eckart K, Holowiecki J, Giebel S, Aschan J, Zander A, Kröger N, Doelken G, Freund M. Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. *Ann Hematol*. 2004;83 Suppl 1:S70-1.
334. Fehse B, Ayuk FA, Kröger N, Fang L, Kuhlcke K, Heinzelmann M, Zabelina T, Fauser AA, Zander AR. Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. *Blood*. 2004 Nov 15;104(10):3408-9.
335. Tiercy JM, Passweg J, van Biezen A, Zander A, Kröger N, Gratwohl A, Chapuis B, Helg C, Brinch L, Cornelissen J, Oudshoorn M, Ruutu T, Volin L, Niederwieser D, Roosnek E; Chronic Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT). Isolated HLA-C mismatches in unrelated donor transplantation for CML. *Bone Marrow Transplant*. 2004 Aug;34(3):249-55.
336. Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. *J Clin Oncol*. 2004 Jun 15;22(12):2273-83.
337. Schetelig J, Bornhäuser M, Kiehl M, Schwerdtfeger R, Kröger N, Runde V, Zabelina T, Held TK, Thiede C, Fauser AA, Beelen D, Zander A, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis. *Bone Marrow Transplant*. 2004 Mar;33(5):483-90.

2003

338. Shimoni A, Kröger N, Zander A, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Imatinib mesylate (ST1571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. *Leukemia* 2003; 17: 290-297
339. Krüger WH, Lange A, Badbaran A, Gutensohn K, Kröger N, Zander AR. Detection of disseminated epithelial cancer cells by liquid culture-factors interfering with the standardization of assays. *Cytotherapy* 2003; 5 (3): 252-258
340. Schetelig J, Thiede C, Bornhäuser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kröger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. *J Clin Oncol* 2003; 21 (14): 2747-53
341. Zander AR, Kröger N, Schleuning M, Finke J, Zabelina T, Beelen D, Schwerdtfeger R, Baumann H, Bornhäuser M, Ehninger G, Fauser AA, Kiehl M, Trensche R, Ottinger HD, Bertz H, Berger J, Kolb HJ, Schaefer UW. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). *Bone Marrow Transplant* 2003; 32 (4): 355-61
342. Einsele H, Bamberg M, Budach W, Schmidberger H, Hess CF, Wormann B, Meisner C, Straka C, Hebart H, Trümper L, Kröger N, Zander AR, Hegewisch-Becker S, Hossfeld DK, Schmidt H, Müller P, Schlimok G, Hertenstein B, Peest D, Metzner B, Frickhofen N, Kanz L, Bensinger W. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. *Bone Marrow Transplant*. 2003 Sep;32(6):593-9.
343. Fehse N, Fehse B, Kröger N, Zabelina T, Freiburger P, Krüger W, Kabisch H, Erttmann R, Zander AR. Influence of anti-thymocyte globulin as part of the conditioning regimen on immune reconstitution following matched related bone marrow transplantation. *J Hematother Stem Cell Res* 2003;12 (2): 237-42
344. Weber M, Kröger N, Langer F, Hansen A, Zabelina T, Eifrig B, Hossfeld DK, Zander AR. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2003; 31(9): 817-22

2002

345. **Begemann PGC, Hassan HT, Kröger N, Krüger W, Kabisch H, Zander AR:** Correlation of time to platelet engraftment with amount of transplanted CD34⁺CD41⁺ cells after allogeneic bone marrow transplantation. *Journal of Hematotherapy and Stem Cell Research*, 2002; 11 (2): 321-6
346. **Fruehauf S, Veldwijk MR, Berlinghoff S, Basara N, Baum C, Flasshove M, Hegewisch-Becker S, Kröger N, Licht T, Moritz T, Zeller WJ, and Laufs S:** Gene therapy for sarcoma. *Cells Tissues Organs* 2002; 172 (2): 133-144
347. **Tögel F, Kröger N, Koriath F, Fehse B, Zander AR:** Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between realtime quantitative and nested PCR. *J of Hematotherapy* 2002; Dec; 11(6); 971-6
348. **Schetelig J, Kröger N, Held TK, Thiede C, Krusch A, Zabelina T, Dubiel M, Rick O, Bornhäuser M, Ehninger G, Zander AR, Siegert W:** Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. *Haematologica* 2002; 87 (3): 299-305
349. **Hanel M, Kröger N, Sonnenberg S, Bornhäuser M, Krüger W, Kroschinsky F, Hanel A, Metzner B, Birkmann J, Schmid B, Hoffknecht MM, Fiedler F, Ehninger G, Zander AR:** Busulfan, cyclophosphamide and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. *Ann Hematol* 2002; 81 (2): 96-102
350. **Gutensohn K, Geidel K, Kröger N, Eifrig B, Crespeigne N, Kuehn P:** Platelet function testing in apheresis products: flow cytometric, resonance thrombographic (RTG) and rotation thrombelastographic (roTEG) analyses. *Transfus Apheresis Sci* 2002; 26 (3): 147-55
351. **Hoeller U, Heide J, Kröger N, Krueger W, Jaenicke F, Alberti W:** Radiotherapy after high-dose chemotherapy and peripheral blood stem cell support in high-risk breast cancer. *Int J Radiat Oncol Biol Phys* 2002; 53 (5): 1234-9
352. **Gutensohn K, Geidel K, Brockmann M, Siemenssen M, Krüger W, Kröger N, Kühnl P.** Binding of activated platelets to WBC in vivo after transfusion. *Transfusion* 2002; 42 (10): 1373-80
353. **Hauber HP, Mikkila A, Erich JM, Kröger N, Meyer A, Schoder V, Zander AR, Pforte A.** TNFalpha, interleukin-10 and interleukin-18 expression in cells of the bronchoalveolar lavage in patients with pulmonary complications following bone marrow or peripheral stem cell transplantation. A preliminary study. *Bone Marrow Transplant* 2002; 30 (8): 485-90
354. **Graf Finckenstein F, Zabelina T, Durken M, Dahlke J, Kröger N, Krüger W, Janka-Schaub G, Erttmann R, Zander AR, Kabisch H.** Unrelated Donor Stem Cell Transplantation in Children: Low Toxicity using a GvHD-Prophylaxis Regimen with CSA, MTX, Metronidazole, iv-Immunoglobulin and ATG. *Klin Padiatr* 2002; 214 (4): 206-11
355. **Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U, Ayuk FA, Renges H, Panse J, Erttmann R, Zander AR.** Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. *British Journal of Haematology* 2002; 119: 769-772

2001

356. **Bornhäuser M, Kiehl M, Siegert W, Schetelig J, Hertenstein B, Martin H, Schwerdtfeger R, Sayer HG, Runde V, Kröger N, Theus C, Ehninger G:** Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. *British Journal of Haematology* 2001; 115 (1): 119-24
357. **Krüger WH, Kröger N, Tögel F, Renges H, Badbaran A, Hornung-Jung R, Gutensohn K, Giesecking F, Jänicke F, Zander AR:** Disseminated breast cancer cells prior to and after high-dose therapy. *J Hematother Stem Cell Res* 2001; 10 (5): 681-9
358. **Kruger WH, Hornung RJ, Hertenstein B, Kern WV, Kröger N, Ljungman P, Zander AR:** Practices of infectious disease prevention and management during hematopoietic stem cell transplantation: a survey from the European group for blood and marrow transplantation. *J Hematother Stem Cell Res* 2001; 10 (6): 895-903

359. **Tögel F, Datta C, Badbaran A, Kröger N, Renges H, Giesecking F, Jänicke F, Zander AR, Krüger W:** Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells. *J Hematother StemCell Res* 2001; 10 (1): 141-5
360. **Krüger W, Kröger N, Tögel F, Badbaran A, Renges H, Giesecking F, Gutensohn F, Jänicke F, Zander AR.** Influence of Preharvest Tumor Cell Contamination in Bone Marrow or Blood Does Not Predict Resultant Tumor Cell Contamination of Granulocyte Colony-Stimulating Factor Mobilized Stem Cells. *J Hematother StemCell Res* 2001; 10 (2): 303-7
361. **Hanel M, Kröger N, Kroschinsky F, Birkmann J, Hanel A, Herbst R, Naumann R, Friedrichsen K, Ehninger G, Zander AR, Fiedler F.** Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. *J Cancer Res Clin Oncol* 2001; 127 (6): 387-95
362. **Fehse B, Chukhlovina A, Kuhlcke K, Marinetz O, Vorwig O, Renges H, Krüger W, Zabelina T, Dudina O, Finckenstein FG, Kröger N, Kabisch H, Hochhaus A, Zander AR:** Real-time quantitative Y-chromosome-specific pcr (qycs-pcr) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. *J Hematother Stem Cell Res* 2001; 10 (3): 419-25
363. **Krüger WH, Jung R, Detlefsen B, Mumme S, Badbaran A, Brandner J, Renges H, Kröger N, and Zander AR:** Interference of cytokeratin-20 and mammaglobin-reverse-transkriptase polymerase chain assays designed for the detection of disseminated cancer cells. *Medical Oncology* 2001; 18 (1) 33-38

2000

364. **Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kröger N, Parwaresch R, Kneba M, Schmitz N, Haas R.** The impact of timing of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies of 46 patients. *The Hematology Journal* 2000; 1: 87-94.
365. **Gutensohn K, Alisch A, Krüger W, Kröger N, Kühnl P.** Extracorporeal plateletpheresis induces the interaction of activated platelets with white blood cells. *Vox sanguinis* 2000; 78: 101-105.
366. **Krüger W, Jung R, Kröger N, Gutensohn K, Fiedler W, Neumaier M, Jänicke F, Wagener C, Zander AR.** Sensitivity of assays designed for detection of disseminated epithelial cells is influenced by cell separation methods. *Clin Chem* 2000; 46: 435-436.
367. **Hänel M, Kröger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hänel A, Krüger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR.** ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas. *Annals of Hematology* 2000; 79: 304-311.
368. **Krüger W, Lohner R, Jung R, Kröger N, Zander AR.** Expression of human milk fat globulin proteins in cells of haematopoietic origin. *British Journal of Cancer* 2000; 83: 874-879.
369. **Krüger W, Kröger N, Zander AR.** MUC1 expression in hematopoietic tissue. *J Hematother Stem Cell Res* 2000; 9: 409-410.
370. **Krüger W, Datta C, Badbaran A, Tögel F, Gutensohn K, Carrero I, Kröger N, Jänicke F, Zander AR.** Immunomagnetic tumor cell selection implications for the detection of disseminated cancer cells. *Transfusion* 2000; 40: 1489-1493.
371. **Carrero I, Kröger N, Krüger W, Schaefer P, Kuehnl P, Gutensohn K:** A two-year flow-cytometric immune surveillance of plateletpheresis donors. *Infus Ther Transfus Med* 2000; 27: 302-306

1999

372. **Zeller W, Kröger N, Berger J, Krüger W, Dierlamm J, Stockschröder M, Gutensohn K, Hossfeld DK, Zander AR.** Expression of the adhesion molecules CD49d and CD49e on G-CSF mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells. *J Hematother Stem Cell Res* 1999; 8: 539-546.
373. **Mross K, Kröger N, Herbst K, Gastl G, Hossfeld D.** Alteration in Epirubicin pharmacokinetics and metabolism by Dexverapamil: results from a phase II study in patients with metastatic breast cancer. *Onkologie* 1999; 22: 35-40.
374. **Hassan HT, Hinz T, Kröger N, Zeller W, Zander AR.** Factors influencing platelet recovery after autologous transplantation of G-CSF mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients. *Clin Lab Haem* 1999; 21: 21-27.

375. **Krüger W, Rüssmann B, Kröger N, Salomon C, Ekopf N, Elsner HA, Kaulfers PM, Mack D, Fuchs N, Dürken M, Kabisch H, Zander AR.** Early infections in patients undergoing bone marrow or blood stem cell transplantation-a 7 year single centre investigation of 409 cases. *Bone Marrow Transplantation* 1999; 23: 589-597.
376. **Zander AR, Zabelina T, Kröger N, Renges H, Krüger W, Löliger C, Dürken M, Stockschräder M, de Wit M, Wacker-Backhaus G, Bielack S, Jaburg N, Rüssmann B, Erttmann, Kabisch H.** Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. *Bone Marrow Transplantation* 1999; 23: 889-893.
377. **Krüger W, Kröger N, Gutensohn K, Tögel F, Zander AR.** Cell selection in marrow and stem cell transplantation. *Infus Ther Transfus Med* 1999; 26: 130-138.
378. **Krüger W, Tögel F, Rössing S, Kröger N, Zander AR.** Improvement of breast cancer cell detection by immunomagnetic enrichment. *Cytotherapy* 1999; 1 (1): 135-139.
379. **Krüger W, Tögel F, Kröger N, Rössing S, Giesecking F, Gutensohn K, Lindner C, Jänicke F, Zander AR.** Tumour cell detection in G-CSF mobilised stem cell harvest of patients with breast cancer. *Medical Oncology* 1999; 16: 17-22.
380. **Dürken M, Horstmann M, Bieling P, Erttmann, Kabisch H, Löliger C, Schneider EM, Hellwege HH, Krüger W, Kröger N, Zander AR, Janka GE.** Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single centre experience of 12 patients. *Brit J Haematology* 1999, 106; 1052-1058.
381. **Gutensohn K, Carrero I, Krüger W, Kröger N, Schafer P, Lüdemann K, Kühnl P.** Semi-automated flow cytometric analysis of CD34 expressing hematopoietic cells in peripheral blood progenitor cell apheresis products. *Transfusion* 1999; 39: 1220-1226.

1998

382. **Hegewisch-Becker S, Staib F, Loning T, Pichlmeier U, Kröger N, Reymann A, Hossfeld DK.** No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. *Ann Oncol* 1998; 9(1): 85-93
383. **Krüger W, Gruber M, Hennings S, Fehse N, Fehse B, Gutensohn K, Kröger N, Zander AR:** Purging and haematopoietic progenitor cell selection by CD34+ cell separation. *Bone Marrow Transplantation* 1998; 21: 665-671.
384. **Lehnert M, Mross K, Schüller J, Thuerlimann B, Kröger N, Kupper H.** Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. *Br J Cancer* 1998; 77(7): 1155-1163.
385. **Burmeister MA, Standl T, Brauer P, Ramsperger K, Kröger N, Zander AR, Schulte am Esch J.** Safety and efficacy of spinal vs general anesthesia in bone marrow harvesting. *Bone Marrow Transplantation* 1998; 21; 1145-48.
386. **Krüger W, Kröger N, Rüßmann B, Renges H, Kabisch H, Zander AR.** Treatment of mycotic infections after haematopoietic progenitor cell transplantation with liposomal Amphotericin B. *Bone Marrow Transplantation* 1998; 22 (Suppl 4): 10-14.
387. **Jung R, Krüger W, Hosch S, Holweg M, Kröger N, Wagner C, Neumaier M, Zander AR.** Specificity of rtPCR assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro. *Brit J Cancer* 1998; 78 (9): 1194-1998.

1997

388. **Zander AR, Berger C, Kröger N, Stockschräder M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann, Schönrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Wit M, Hossfeld DK, Weh HJ:** High-Dose Chemotherapy with Busulfan, Cyclophosphamide and VP 16 as Conditioning Regimen for Allogeneic Bone Marrow Transplantation for Patients with Acute Myeloid Leukemia in First Complete Remission. *Clin Cancer Res* 1997; 3: 2671-75.
389. **Stockschräder M, Hassan HT, Zeller W, Krüger W, Clausen J, Löliger C, Tom Diek A, Kröger N, Link H, Kabisch H, Hossfeld DK, Zander AR.** Allogeneic transplantation with CD34+-selected cells. *Leukemia and Lymphoma* 1997; 25: 145-151.

390. **Krüger W, Stockschräder M, Sobottka I, Betker R, de Wit M, Kröger N, Grimm J, Arland M, Fiedler W, Erttmann R, Zander AR.** Antimycotic therapy with liposomal Amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation. *Leukemia and Lymphoma* 1997; 24: 491-499.

1996 und älter

391. **Zander AR, Krüger W, Kröger N, Damon L, Königsmann et al.** High-Dose Mitoxantrone with Thiotepa, Cyclophosphamide and Autologous Stem Cell Rescue For High-Risk Stage II and Stage III Breast Cancer. *Bone Marrow Transplantation* 1996; 18 (Suppl 1): 24-25.
392. **Krüger W, Krzianowski C, Holweg M, Stockschräder M, Kröger N, Jung R, Mross K, Jonat W, Zander AR.** Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients. *J Cancer Res Clin Oncol* 1996; 122: 679-686.
393. **Zeller W, Gutensohn K, Stockschräder M, Dierlamm J, Kröger N, Köhne G, Hummel K, Kabisch H, Weh HJ, Kühnl P, Hossfeld DK, Zander AR.** Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. *Bone Marrow Transplantation* 1996; 17: 709-713.
394. **Dierlamm J, Michaux L, Kröger N, Wlodarska I, Martiat P, Zeller W, Seeger D, Mecucci C, van den Berghe H, Hossfeld DK:** Ider(9)t(q34;q11) is a Recurrent Chromosomal Abnormality in Acute Lymphoblastic Leukemia and Lymphatic Blastic Phase of Chronic Myelogenous Leukemia. *Cancer Genet Cytogenetic* 1996; 89:109-113.
395. **Thürlimann B, Kröger N, Lehnert A, Greiner J, Mross K, Schüller J, Schernmacher E, Schumacher K, Gast G, Hartlapp J, Kupper H:** Dexverapamil to Overcome Epirubicine Resistance in Advanced Breast Cancer. *J Cancer Res Treat* 1995; 121 (Suppl 3): 3-6.
396. **Krüger WH, Stockschräder M, Rüßmann BC, Hoffknecht M, Sobottka I, Kröger N, Zander AR:** Experience with Liposomal Amphotericin B in 60 Patients Undergoing High-Dose Therapy and Bone Marrow or Peripheral Blood Stem Cell Transplantation. *Br J Hematol* 1995; 91: 684-90.